An interventional study of Magneto 150 holmium laser and Moses 2.0 holmium laser in Enlarged Prostate (BPH) and Benign Prostatic Hyperplasia, sponsored by Northwestern University. Recruiting at 1 site in United States. Open to male participants aged 18 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Northwestern University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Prostatic Hyperplasia by Northwestern University — 4 open to participants now, 5 under way, none of them phase 3. Prostatic Hyperplasia · Northwestern University.
Among the 10 studies in Prostatic Hyperplasia by Northwestern University, this one is one of 3 that started in 2026, is one of 7 with no phase, and was the 10th registered.
831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.
Browse Prostatic Hyperplasia studies →4 of the 10 studies in Prostatic Hyperplasia by Northwestern University are open now, in 1 country. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18–100 · Men only · Healthy volunteers
Northwestern University · Sites in United States
Ages 50+ · Men only
Northwestern University · Sites in United States
Ages 50–80 · Men only · Healthy volunteers
By country, each count listing its studies:
Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.
This study: 18 Years to 100 Years · male · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 180 is above the median of 94 across 629 interventional studies indexed under Prostatic Hyperplasia.
Median enrollment 48 across the 9 interventional studies, 300 across the 1 observational. Of the 5 that completed or were terminated, 4 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Northwestern University is the lead sponsor of 1,424 studies on the registry; 199 are open to participants now.
Of its 105 completed or terminated interventional studies of FDA-regulated products, 78 (74%) have results posted.
4 of the studies in Prostatic Hyperplasia by Northwestern University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05898932Northwestern UniversityEnhanced Clinical Decisions for Management of Benign Prostatic Hyperplasia Using Patient-Reported Outcomes | 2027-04 |
| NCT07631286Northwestern UniversityEjaculatory-Sparing HoLEP vs Standard HoLEP | 2027-05 |
| NCT07632742Northwestern UniversityMoses 2.0 vs Magneto for HoLEP - a Randomized Controlled Trial | 2027-06 |
| NCT07580404Northwestern UniversityEmsella for Reducing tSUI After HOLEP | 2027-07 |
Add all 4 to your calendar (.ics) → With an account.
Among the 10 studies in Prostatic Hyperplasia by Northwestern University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The objective of this study is to compare the Magneto 150 holmium laser to the current MOSES 2.0 technology to see if there is a benefit in decreased hemostasis time intraoperatively.
The Magneto 150 is a high-powered 150W holmium laser that offers similar pulse-modulation benefits of MOSES 2.0, which facilitates effective dissection and enucleation of the tissue plane while also offering a new first-of-its kind proprietary Magneto setting which allows for very low peak power of 500W and longer pulse duration which allows for better hemostasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
HoLEP procedure performed using the Moses 2.0 holmium laser
Device: Moses 2.0 holmium laser
HoLEP procedure performed using Magneto 150 holmium laser
Device: Magneto 150 holmium laser
The HoLEP procedure will be performed using the Quanta Magneto 150 holmium laser
The HoLEP procedure will be performed using the Moses 2.0 holmium laser
Mean hemostasis time
Overall intraoperative hemostasis time
Time frame: During surgery
Mean (average) enucleation time
Time taken to surgically remove excess prostate tissue while leaving the shell of the prostate intact and within the body.
Time frame: During surgery
Total operative time
Time taken from official procedure start to completion (not accounting for the time that the patient is wheeled in, prepped and out of the operating room).
Time frame: During surgery
Hemostasis efficiency
minutes/gram (prostate tissue removed)
Time frame: During surgery
Plan to share: No
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Jun 2027, 13 months after the start.
Of 155 non-industry interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 48. This study's planned 13 months is below that.
Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.
Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → May 2026, on Oct 15, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.